StreetInsider.com News Articles

Form 4 PFIZER INC For: Oct 15 Filed by: BOURLA ALBERT

Fri, 16 Oct 2026 18:53:00 -0400

si-local-file:///var/storage/secattach/20261016/27198938.html

Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald

Fri, 16 Oct 2026 07:33:04 -0400

Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $28.00 price target on Pfizer (NYSE: PFE).

The analyst commented, "Our 12-month $28 price target for Pfizer shares is based on our DCF analysis. We assume an 8.5% WACC and -1% terminal growth, in-line with our standard assumption for large biopharma companies with declining revenues into our terminal value year. We also apply a 19% long-term tax rate."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $29.44 yesterday.

Form 4 PFIZER INC For: Oct 13 Filed by: BOURLA ALBERT

Wed, 14 Oct 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20261014/27187684.html

Pfizer to present infectious disease data at IDWeek 2026

Wed, 14 Oct 2026 06:46:17 -0400

Pfizer Inc. (NYSE: PFE) plans to present data from more than 50 research abstracts at the IDWeek 2026 congress in Washington, D.C., scheduled for October 21-24, 2026, according to a company press release.

The presentations will include 12 oral sessions covering vaccines and therapies across several infectious diseases. Key data include Phase 2 immunogenicity results for a 25-valent pneumococcal conjugate vaccine candidate in healthy infants, and Phase 3 efficacy and safety results from the VALOR study of LB6V, a Lyme disease vaccine candidate developed with Valneva, in participants aged five and older. The European Medicines Agency began reviewing a marketing authorization

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

Wed, 14 Oct 2026 06:45:00 -0400

Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases.

“At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

Wed, 14 Oct 2026 06:45:00 -0400

Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases.
“At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies

Guggenheim Reiterates Buy Rating on Pfizer (PFE)

Tue, 13 Oct 2026 07:17:27 -0400

Guggenheim analyst Vamil Divan reiterated a Buy rating and $31.00 price target on Pfizer (NYSE: PFE).
The analyst commented: "We are updating our PFE model ahead of the company's 3Q 2026 earnings release. We forecast 3Q revenues of $16.16Bn (vs. Visible Alpha Consensus of $15.9Bn) and EPS of $0.77 (vs. Consensus of $0.75), which includes the ~$650M acquired IPR&D charge for the Innovent (1801-HK) licensing deal. Our FY 2026 estimates of $62.5Bn and $2.99 (vs. Consensus of $62.2Bn and $2.97) sit at the top of management guidance of $60.5-62.5Bn in sales and $2.80-3.00 in EPS. Our Eliquis and COVID estimates account

Pfizer (PFE) PT Raised to $30 at JPMorgan

Fri, 09 Oct 2026 08:06:38 -0400
JPMorgan analyst Chris Schott raised the price target on Pfizer (NYSE: PFE) to $30.00 (from $28.00) while maintaining a Neutral rating.

Pfizer (PFE) PT Raised to $28 at Cantor Fitzgerald on Growing Sector Tailwinds

Thu, 08 Oct 2026 07:17:45 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $28.00 (from $27.00) while maintaining a Neutral rating.
The analyst commented, "Lines have largely been drawn into MEVPRO-1, leaving shares gated on the readout. Questions around longer-term growth and dividend sustainability persist, but it remains unclear how much the print will add on either front...Pfizer shares have found a bid this quarter (+16% QTD vs +11% QTD peers), supported by sector tailwinds, some growing positivity towards key pipeline assets (mevro, tilrekimig, breast pipeline), and a view that the <9x multiple on ’27 estimates was too cheap. To

Pfizer (PFE) PT Raised to $28 at Cantor Fitzgerald on Growing Sector Tailwinds

Thu, 08 Oct 2026 07:17:45 -0400

Cantor Fitzgerald analyst Carter Gould raised the price target on Pfizer (NYSE: PFE) to $28.00 (from $27.00) while maintaining a Neutral rating.
The analyst commented, "Lines have largely been drawn into MEVPRO-1, leaving shares gated on the readout. Questions around longer-term growth and dividend sustainability persist, but it remains unclear how much the print will add on either front...Pfizer shares have found a bid this quarter (+16% QTD vs +11% QTD peers), supported by sector tailwinds, some growing positivity towards key pipeline assets (mevro, tilrekimig, breast pipeline), and a view that the <9x multiple on ’27 estimates was too cheap. To

FDA approves Pfizer's Tukysa as front-line maintenance for HER2+ breast cancer

Wed, 07 Oct 2026 12:57:18 -0400

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has approved Tukysa (tucatinib) in combination with trastuzumab and pertuzumab as a maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.

The approval is supported by results from the Phase 3 HER2CLIMB-05 trial, a randomized, double-blind, placebo-controlled study. The trial showed a 35.9% reduction in the risk of disease progression or death among patients treated with the Tukysa regimen compared to placebo combined with trastuzumab and pertuzumab, with a hazard ratio of 0.64 (95% CI: 0.51–0.80; p<0.0001).

Median progression-free survival in the Tukysa

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

Wed, 07 Oct 2026 12:57:00 -0400

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

Wed, 07 Oct 2026 12:57:00 -0400

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance

Pfizer to cut 330 jobs at Sicily plant, unions say

Wed, 07 Oct 2026 10:28:40 -0400

Investing.com -- Pfizer Inc plans to eliminate approximately 330 positions at its Sicily facility in Italy, labor unions announced on Wednesday. The cuts represent about 60% of the plant's current workforce of 550 employees.
Negotiations between Pfizer and Italy's industry ministry on Tuesday evening in Rome did not produce an agreement, according to a joint statement from the CGIL, CISL and UIL unions.
Italy's industry ministry stated that issues discussed during the meeting would form the basis for continued dialogue. Industry Minister Adolfo Urso is scheduled to visit the Sicily plant on October 23, with additional talks between Pfizer and the ministry

Pfizer (PFE) PT Raised to $33 at Scotiabank

Wed, 07 Oct 2026 06:35:10 -0400
Scotiabank analyst Louis Chen raised the price target on Pfizer (NYSE: PFE) to $33.00 (from $30.00) while maintaining a Sector Outperform rating.

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Tue, 06 Oct 2026 19:30:00 -0400

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –

TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Tue, 06 Oct 2026 19:30:00 -0400

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –

TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Tue, 06 Oct 2026 19:30:00 -0400

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –

TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Tue, 06 Oct 2026 19:30:00 -0400

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –

TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503,

Pfizer Declares Fourth-Quarter 2026 Dividend

Tue, 06 Oct 2026 10:00:00 -0400

Pfizer Board of Directors approves fourth-quarter 2026 cash dividend of $0.43 per share

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026.
As part of its capital allocation strategy, Pfizer is committed to maintaining, and over the longer term, growing the dividend. The fourth-quarter 2026 cash dividend will be the 352nd consecutive quarterly dividend paid by Pfizer.
About Pfizer: Breakthroughs That Change

Pfizer Declares Fourth-Quarter 2026 Dividend

Tue, 06 Oct 2026 10:00:00 -0400

Pfizer Board of Directors approves fourth-quarter 2026 cash dividend of $0.43 per share

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026.
As part of its capital allocation strategy, Pfizer is committed to maintaining, and over the longer term, growing the dividend. The fourth-quarter 2026 cash dividend will be the 352nd consecutive quarterly dividend paid by Pfizer.
About Pfizer: Breakthroughs That Change

Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment

Fri, 02 Oct 2026 11:18:30 -0400

Pfizer (NYSE: PFE) presented results from two Phase 3 trials showing that its drug Litfulo (ritlecitinib) met co-primary endpoints for the treatment of nonsegmental vitiligo, according to a company press release. The data were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.
In the TRANQUILLO 2 trial, which evaluated a 100 mg daily dose in 1,567 adults, 21.86% of patients achieved at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) compared with 2.40% on placebo. For total body repigmentation, 13.02% of patients on Litfulo achieved at least 50% improvement in the

Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment

Fri, 02 Oct 2026 11:18:30 -0400

Pfizer (NYSE: PFE) presented results from two Phase 3 trials showing that its drug Litfulo (ritlecitinib) met co-primary endpoints for the treatment of nonsegmental vitiligo, according to a company press release. The data were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.
In the TRANQUILLO 2 trial, which evaluated a 100 mg daily dose in 1,567 adults, 21.86% of patients achieved at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) compared with 2.40% on placebo. For total body repigmentation, 13.02% of patients on Litfulo achieved at least 50% improvement in the

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

Fri, 02 Oct 2026 11:15:00 -0400

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral systemic therapy for adults with nonsegmental vitiligo

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.
In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo. These

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

Fri, 02 Oct 2026 11:15:00 -0400

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral systemic therapy for adults with nonsegmental vitiligo

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.
In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo. These